Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market expansion proponents

Executive Summary

Underneath the clearly demarcated party lines of the debate, there were some out-of-character comments. Minority Leader Rep. Gephardt, for example, became a cheerleader for wider drug use during his attack on the bill. Explaining why the drug program should be a benefit and not insurance, Gephardt declared, "when we come to prescription drug benefits, everybody makes a claim, because everybody needs prescription drugs." California Democrat Rep. Stark got caught up in the description of a more generous Democratic benefit. "We are begging to spend this surplus and not waste it on a relief from the inheritance tax...With that money alone, we could provide an added benefit at a low enough premium and eliminate the copay so that we could include all the Medicare beneficiaries in a generous, dependable benefit with a reliable premium that would be the same across the country and allow the seniors to get their drugs from any provider in the country"

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel